The subscription period runs from June 17 through June 26, and the new shares will be listed from July 5.

By Cormac Sheridan Staff Writer DUBLIN, Ireland – Royalty Pharma's bitter and protracted takeover battle for Elan Corp

Elan said it did so because Royalty Pharma, in response to Elan's complaint, was forced to revise its tender offer documents to provide significant amounts of additional information.

Elan said it did so because Royalty Pharma, in response to Elan's complaint, was forced to revise its tender offer documents to provide significant amounts of additional information.

By Cormac Sheridan Staff Writer German biotech received a badly needed boost this week with the news that GlaxoSmithKline plc was in-licensing MOR103, an antibody in clinical development in rheumatoid arthritis (RA) and multiple sclerosis (MS) at veteran antibody developer Morphosys AG, in return for an up-front payment of €22.5 million (US$29 million), plus another potential €423 million in milestones linked to its progress through clinical development, regulatory approval and sales

I wouldn't rule it out at some stage," Moroney said.

And, by Munos's reckoning, the industry needs a lot more of them – at the very highest levels of leadership.

For now, that being pursued by Flanders seems to be working.

I wouldn't rule it out at some stage," Moroney said.

For now, that being pursued by Flanders seems to be working.

The meeting closed Thursday.

In deploying £253m in firepower with a 10 percent placing, BTG has assembled a world-leading interventional medicine business with significant growth potential as therapies and medical devices become increasingly targeted."

The company has also set its sights on clinical centers in the U.S.

The company has also set its sights on clinical centers in the U.S.

In deploying £253m in firepower with a 10 percent placing, BTG has assembled a world-leading interventional medicine business with significant growth potential as therapies and medical devices become increasingly targeted."

By Cormac Sheridan Staff Writer DUBLIN, Ireland – Elan Corp

It would be a stretch for us to do two of them a year," Spork said.

It would be a stretch for us to do two of them a year," Spork said.

If they don't deliver on that potential, Elan's shareholders will have an expensive jigsaw puzzle on their hands.